Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance

LabiotechNew names, new narratives: Why biotechs decide to rebrand

PharmaVoiceThe biotech market is rebounding. So where are the executive jobs?

FierceBiotechSoligenix axes lymphoma program after phase 3 setback, mulls M&A options

FierceBiotechBeyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMP

FierceBiotechHow NEC's AI and oral delivery system are redefining personalized cancer therapy

Endpoints NewsLilly puts its stamp at #EHA26 with Jaypirca combo data in CLL, first clinical data from Ajax buyout

BioPharma DiveCeliac disease is entering a new era of therapeutic innovation

BioPharma DivePlanning a successful pivot from lab to clinic

Science Daily BiotechScientists turned red lettuce green and something surprising happened

Endpoints NewsHMNC Brain Health raises $50M Series B to advance two depression drugs

eLifeExposure to false cardiac feedback alters pain perception and anticipatory cardiac frequency

eLifeNuclear CK1δ as a critical determinant of PER:CRY complex dynamics and circadian period